Comparison of two regimens of weekly paclitaxel plus gemcitabine in patients with metastatic breast cancer: propensity score-matched analysis of real-world data

• Egile Nagusiak: Chengcheng Gong (Egilea), Yizhao Xie (Egilea), Yannan Zhao (Egilea), Yi Li (Egilea), Jian Zhang (Egilea), Leiping Wang (Egilea), Jun Cao (Egilea), Zhonghua Tao (Egilea), Xichun Hu (Egilea), Biyun Wang (Egilea)
• Formatua: Liburua
• Argitaratua: SAGE Publishing, 2022-12-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Purpose: Weekly gemcitabine + paclitaxel (wGT) administration is widely applied in real-world clinical practice. The 28-day and 21-day regimens of wGT are the most widely accepted regimens. We evaluated the efficacy and safety of wGT administration in patients with metastatic breast cancer (MBC) and...